NCT07624617Recruiting
Fast-Her: Fasting Effects on Breast Cancer Treatment
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
We hypothesize that promoting a fasting state will strengthen the anti-cancer effects of PI3K inhibitors in metastatic breast cancer (MBC) treatment. The primary objective of this study is to assess acceptability of prolonged fasting in this population.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 28 May 2026
- Start date
- 18 May 2026
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- University of Minnesota
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07624617
What you commit to
- Study type: Interventional
- Planned participants: 15
- From 18 May 2026 to the primary completion date, 1 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in other dietary intervention studies
Other illness
- Type 1 diabetes mellitus
- History of severe hypoglycemia
- Eating disorders or contraindications to fasting
- Significant gastrointestinal disorders affecting food absorption
Lab values
- Uncontrolled type 2 diabetes (HbA1c \>9.0%)
- A history of significantly abnormal lab results within 4 weeks of consent date, such as hematologic (Hgb \< 10.0, platelets \< 100), hepatic (LFTs \> 2X nl), renal (Cr \> 1.5)
Other
- Pregnancy or breastfeeding
- Unable to fast for medical reasons
Who the study is looking for
- Age ≥18 years
- Histologically confirmed metastatic breast cancer
- Menopausal or medically ovarian suppressed
- Currently receiving capivasertib therapy (2 tablets twice daily, 4 days per week)
- Stable on current capivasertib regimen for at least 2 weeks
- an ECOG performance status of 0-1
- BMI ≥25kg/m2
- Able to provide informed consent
- Willing to comply with study procedures including CGM wear, food tracking by mCC app and dietary modifications
- Access to smartphone or tablet for mobile application use
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Minnesota Coordinator of this site? Confirm its status | Minneapolis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.